Participated · Seed · Mar 2026

Flourish Care, founded in 2020, operates a maternal healthcare platform that matches families with credentialed doulas and delivers a hybrid model of in-person and virtual support. The platform powers referrals, care coordination, and insurance reimbursement and integrates into workflows for health plans, obstetrics, hospitals, FQHCs, and community organizations. Flourish Care reports it has supported thousands of families and is available to more than 20 million covered lives through commercial plans and Medicaid. The company is building an AI-driven risk-prediction engine using clinical and community-reported data to identify patients who may benefit from additional support earlier in pregnancy. Flourish Care positions its model as improving maternal outcomes, reducing unnecessary interventions, and lowering costs as states expand reimbursement for doula care.

Participated · Series A · Dec 2021

X-Therma is a San Francisco, CA–based biotechnology company developing a convergent biopreservation platform and cold chain technology for regenerative medicine and organ preservation. Led by CEO Xiaoxi Wei, the company aims to enable safe, on-demand organs, engineered tissues, cell and gene therapies, and vaccines by overcoming time-sensitive limitations. Its product pipeline includes XT-Thrive and XT-NoVo for regenerative medicine and cell therapy, and XT-ViVo and TimeSeal for organ preservation for transplantation. XT-ViVo and TimeSeal have received FDA Breakthrough Device designation. X-Therma raised $22.4M in a Series B to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status. The round was led by Starling Locke Capital and Lorea, with participation from new and existing investors. X-Therma develops a nontoxic, biomimetic peptoid-based biopreservation platform for organ preservation and cell, gene, and tissue therapies. Its flagship products include XT-Thrive, a DMSO-, serum-, and protein-free chemically defined cryopreservation solution, and organ preservation solutions XT-ViVo and TimeSeal. The company reports a demonstrated extension of organ shelf-life from hours to days in collaboration with a Johns Hopkins surgeon and is positioning its technology to enable global organ banking and off-the-shelf living medicines. X-Therma plans to scale commercialization of cGMP-grade XT-Thrive to meet customer demand from cell and gene therapy and tissue engineering users, and to accelerate regulatory efforts for organ preservation through its partnership with Johns Hopkins University. The company will expand its multidisciplinary team, hiring remotely for roles tied to its San Francisco Bay Area headquarters and Austria subsidiary. X-Therma has also received over $10M in contracts and grant support from the U.S. Department of Defense, the National Science Foundation, and the California Institute for Regenerative Medicine.

Participated · Seed · Nov 2021

Cellevolve Bio develops and commercializes cell therapies using an integrated Cellution clinical development and commercialization platform. The company’s stated goal is to build one of the largest cell therapy pipelines by partnering with innovators and advancing promising assets to market. Cellevolve has assembled a founding leadership team and a global scientific and clinical advisory group to support development and commercialization efforts. It has announced an exclusive manufacturing partnership with Resilience to address manufacturing bottlenecks and enable scalable production. The company is actively recruiting for key leadership roles in Development and Manufacturing to support its commercialization plans. Cellevolve emphasizes translating breakthrough science into therapies that can reach patients quickly and at scale.

Participated · Series C · Jun 2021

Lyndra Therapeutics is a clinical-stage biopharmaceutical company developing long-acting oral therapies using its LYNX drug delivery platform. The LYNX platform creates weekly oral medicines enabled by over 50 patented innovations and is licensed exclusively from the Bob Langer and Gio Traverso laboratories at MIT. Lyndra’s lead product candidate is oral weekly risperidone (LYN-005), which is near completion of a pivotal Phase 3 study, and the company is also advancing weekly formulations of dapagliflozin (LYN-045) and aripiprazole (LYN-006). Proceeds from recent financings are intended to support completion of the risperidone Phase 3 trials and continued development of the pipeline of oral weekly therapies. Since its founding, Lyndra has received product funding from the Bill & Melinda Gates Foundation, the NIH, AbbVie, and Gilead Sciences. The company is headquartered in Watertown, MA and operates a GMP manufacturing facility in Lexington, MA. Lyndra Therapeutics develops long-acting oral therapies using its proprietary LYNX drug delivery platform. Its lead candidate, LYN-005 (oral weekly risperidone), has dosed the first participant in a pivotal trial for schizophrenia and schizoaffective disorder. The LYNX platform is designed to deliver a week’s worth of medication in a single oral capsule. The company recently raised capital as part of a larger offering and previously completed a $60.5 million Series C in 2021. Financial updates include a $20.3 million placement from investors as part of the current offering. Lyndra Therapeutics is a clinical-stage biotechnology company pioneering an oral ultra-long-acting, extended-release capsule designed to reside in the stomach and provide linear drug release for a week or longer. Its lead candidate, LYN-005, is a once-weekly oral risperidone formulation that showed encouraging Phase 2 proof-of-concept data indicating a more consistent pharmacokinetic profile and reduced dosing frequency. The company plans to advance LYN-005 into pivotal trials and prepare for U.S. commercialization, with an expected pivotal start later this year and a launch a few years thereafter. Lyndra is expanding its CNS pipeline assets and actively evaluating high-value partnerships across a broad range of disease states. The platform targets areas where non-adherence is a major driver of outcomes, including schizophrenia, diabetes, cardiovascular disease and opioid use disorder. Lyndra has collaborations and funding engagements including the Bill & Melinda Gates Foundation and the NIH, and has raised almost $250 million in total financing inclusive of the most recent round. Lyndra Therapeutics is developing once-monthly oral dosage forms, including a combination contraceptive designed to deliver continuous estrogen and progestin. Its core technology is a star-shaped formulation contained inside a capsule that opens in the stomach, releases active pharmaceutical ingredients consistently for up to a week or longer, and then exits via the gastrointestinal tract. The current program is focused on demonstrating once-monthly gastric residence and building a once-monthly oral combination therapy. Preclinical evaluation will be conducted in collaboration with Routes2Results through additional funding from the Bill & Melinda Gates Foundation. The foundation awarded Lyndra a $13M grant for the contraceptive program and also awarded a separate grant for a long-acting malaria drug. The foundation invested in Lyndra’s recent Series B; those Series B proceeds will be used for Phase II clinical trials, expansion of the Phase I pipeline, and manufacturing scale-up. Lyndra is led by CEO and co-founder Amy Schulman and is based in Watertown, MA. Lyndra Therapeutics develops orally administered ultra-long-acting, sustained-release therapies designed to deliver steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. Its platform uses a star-shaped formulation inside a capsule that opens in the stomach, releases active pharmaceutical ingredients consistently over time, and then exits the gastrointestinal tract safely. The company aims to replace daily dosing with weekly or monthly pills to improve medication adherence, reduce side effects, and lower healthcare costs. To date the dosage form has been safely administered in 50 subjects during Phase I clinical trials in Australia, and Lyndra received a Notice of Allowance from the U.S. Patent and Trademark Office for related intellectual property. Lyndra is moving toward submitting an IND for a long-acting schizophrenia pill in 2019 and anticipates starting a Phase II clinical trial in 2020 while advancing other candidates through Phase I–III. The company recently raised new financing to support clinical development and manufacturing scale-up.